Final analysis of Covaxin efficacy out; vaccine 65.2% effective against Delta variant
The Hindu
The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases
Bharat Biotech's has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and65.2 per cent . The company on Saturday, July 3, 2021, said it concluded the final analysis of Covaxin efficacy from Phase 3 trials. Also read:More Related News

NPCIL is to blame for storage of radioactive waste on site of Kudankulam nuclear power plant: Appavu
Tamil Nadu Speaker Appavu criticizes NPCIL for unsafe nuclear waste storage at Kudankulam, urging better solutions for public safety.












